Combined treatment of nerve growth factor and transcranical direct current stimulations to improve outcome in children with vegetative state after out-of-hospital cardiac arrest.
Human-recombinant nerve growth factor
Intranasal Administration
Neuroprotection
Out-Off Hospital Cardiac arrest
Transcranial Direct current stimulations
Journal
Biology direct
ISSN: 1745-6150
Titre abrégé: Biol Direct
Pays: England
ID NLM: 101258412
Informations de publication
Date de publication:
10 05 2023
10 05 2023
Historique:
received:
22
03
2023
accepted:
01
05
2023
medline:
12
5
2023
pubmed:
11
5
2023
entrez:
10
5
2023
Statut:
epublish
Résumé
Out-of-hospital cardiac arrest (OHCA) is one of the most dramatic events in pediatric age and, despite advanced neurointensive care, the survival rate remains low. Currently, no effective treatments can restore neuronal loss or produce significant improvement in these patients. Nerve Growth Factor (NGF) is a neurotrophin potentially able to counteract many of the deleterious effects triggered by OHCA. Transcranial Direct Current Stimulation (tDCS) has been reported to be neuroprotective in many neurological diseases, such as motor deficit and cognitive impairment. Children with the diagnosis of chronic vegetative state after OHCA were enrolled. These patients underwent a combined treatment of intranasal administration of human recombinant NGF (hr-NGF), at a total dose of 50 gamma/kg, and tDCS, in which current intensity was increased from zero to 2 mA from the first 5 s of stimulation and maintained constant for 20 min. The treatment schedule was performed twice, at one month distance each. Neuroradiogical evaluation with Positron Emission Tomography scan (PET), Single Photon Emission Computed Tomography (SPECT), Electroencephalography (EEG) and Power Spectral Density of the brain (PSD) was determined before the treatment and one month after the end. Neurological assessment was deepened by using modified Ashworth Scale, Gross Motor Function Measure, and Disability Rating Scale. Three children with a chronic vegetative state secondary to OHCA were treated. The combined treatment with hr-NGF and tDCS improved functional (PET and SPECT) and electrophysiological (EEG and PSD) assessment. Also clinical conditions improved, mainly for the reduction of spasticity and with the acquisition of voluntary finger movements, improved facial mimicry and reaction to painful stimuli. No side effects were reported. These promising preliminary results and the ease of administration of this treatment make it worthwhile to be investigated further, mainly in the early stages from OHCA and in patients with better baseline neurological conditions, in order to explore more thoroughly the benefits of this new approach on neuronal function recovery after OHCA.
Sections du résumé
BACKGROUND
Out-of-hospital cardiac arrest (OHCA) is one of the most dramatic events in pediatric age and, despite advanced neurointensive care, the survival rate remains low. Currently, no effective treatments can restore neuronal loss or produce significant improvement in these patients. Nerve Growth Factor (NGF) is a neurotrophin potentially able to counteract many of the deleterious effects triggered by OHCA. Transcranial Direct Current Stimulation (tDCS) has been reported to be neuroprotective in many neurological diseases, such as motor deficit and cognitive impairment. Children with the diagnosis of chronic vegetative state after OHCA were enrolled. These patients underwent a combined treatment of intranasal administration of human recombinant NGF (hr-NGF), at a total dose of 50 gamma/kg, and tDCS, in which current intensity was increased from zero to 2 mA from the first 5 s of stimulation and maintained constant for 20 min. The treatment schedule was performed twice, at one month distance each. Neuroradiogical evaluation with Positron Emission Tomography scan (PET), Single Photon Emission Computed Tomography (SPECT), Electroencephalography (EEG) and Power Spectral Density of the brain (PSD) was determined before the treatment and one month after the end. Neurological assessment was deepened by using modified Ashworth Scale, Gross Motor Function Measure, and Disability Rating Scale.
RESULTS
Three children with a chronic vegetative state secondary to OHCA were treated. The combined treatment with hr-NGF and tDCS improved functional (PET and SPECT) and electrophysiological (EEG and PSD) assessment. Also clinical conditions improved, mainly for the reduction of spasticity and with the acquisition of voluntary finger movements, improved facial mimicry and reaction to painful stimuli. No side effects were reported.
CONCLUSIONS
These promising preliminary results and the ease of administration of this treatment make it worthwhile to be investigated further, mainly in the early stages from OHCA and in patients with better baseline neurological conditions, in order to explore more thoroughly the benefits of this new approach on neuronal function recovery after OHCA.
Identifiants
pubmed: 37165387
doi: 10.1186/s13062-023-00379-5
pii: 10.1186/s13062-023-00379-5
pmc: PMC10170696
doi:
Substances chimiques
Nerve Growth Factor
9061-61-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
24Informations de copyright
© 2023. The Author(s).
Références
Brain Res Dev Brain Res. 2000 Jan 3;119(1):139-53
pubmed: 10648880
Circulation. 2015 Nov 3;132(18 Suppl 2):S465-82
pubmed: 26472996
Pediatr Cardiol. 2012 Mar;33(3):474-83
pubmed: 21842254
J Pharm Sci. 2010 Apr;99(4):1654-73
pubmed: 19877171
Neurology. 2018 Sep 4;91(10):461-470
pubmed: 30089617
Adv Drug Deliv Rev. 2012 May 15;64(7):614-28
pubmed: 22119441
Glia. 2018 Jul;66(7):1395-1416
pubmed: 29473218
Brain Res. 2017 Sep 1;1670:173-184
pubmed: 28652219
Front Aging Neurosci. 2021 Nov 12;13:741168
pubmed: 34867274
Crit Care Med. 2016 Dec;44(12):e1165-e1174
pubmed: 27509385
PM R. 2023 Feb;15(2):222-234
pubmed: 35286007
Brain Res. 1993 May 28;612(1-2):330-5
pubmed: 8330208
Dement Geriatr Cogn Disord. 1998 Sep-Oct;9(5):246-57
pubmed: 9701676
Clin Pharmacokinet. 2001;40(12):907-46
pubmed: 11735609
J Trauma. 2008 Jul;65(1):80-5
pubmed: 18580535
Eur J Phys Rehabil Med. 2018 Aug;54(4):576-590
pubmed: 28901119
Brain Stimul. 2016 Sep-Oct;9(5):641-661
pubmed: 27372845
Front Syst Neurosci. 2018 Jun 27;12:28
pubmed: 29997483
Brain Res. 2007 Jan 5;1127(1):45-51
pubmed: 17113055
NeuroRehabilitation. 2008;23(3):231-7
pubmed: 18560139
J Neurol Sci. 2014 Oct 15;345(1-2):48-55
pubmed: 25128470
J Neurotrauma. 2015 Oct 1;32(19):1429-40
pubmed: 25646580
J Neuropathol Exp Neurol. 2002 Sep;61(9):778-88
pubmed: 12230324
Circulation. 2015 Nov 3;132(18 Suppl 2):S315-67
pubmed: 26472989
Circulation. 2000 Aug 22;102(8 Suppl):I1-11
pubmed: 10964901
J Mot Behav. 2022;54(4):480-489
pubmed: 34913842
J Alzheimers Dis. 1998 Mar;1(1):35-44
pubmed: 12214010
Front Behav Neurosci. 2016 Mar 31;10:57
pubmed: 27065823
Arch Phys Med Rehabil. 1994 Aug;75(8):885-8
pubmed: 8053795
J Am Heart Assoc. 2015 Oct 08;4(10):e002122
pubmed: 26450118
J Med Life. 2019 Jul-Sep;12(3):233-235
pubmed: 31666823
Neurol Clin. 2008 May;26(2):487-506, ix
pubmed: 18514823
Dev Med Child Neurol. 1989 Jun;31(3):341-52
pubmed: 2753238
AJNR Am J Neuroradiol. 2001 Sep;22(8):1561-5
pubmed: 11559506
Growth Factors. 2013 Aug;31(4):115-22
pubmed: 23777359
Circulation. 2002 Oct 22;106(17):2257-62
pubmed: 12390957
Brain Res. 1998 Mar 30;788(1-2):87-94
pubmed: 9554964
Curr Neurol Neurosci Rep. 2017 Feb;17(2):11
pubmed: 28229395
Childs Nerv Syst. 2020 Sep;36(9):2083-2088
pubmed: 32274529
J Neurotrauma. 1994 Feb;11(1):3-33
pubmed: 8201625
J Vis Exp. 2013 Apr 08;(74):
pubmed: 23608783
J Rehabil Med. 2012 Apr;44(4):346-50
pubmed: 22434324
Neuroscience. 2003;120(1):31-40
pubmed: 12849738
J Neurosci. 1995 Feb;15(2):1567-76
pubmed: 7869118
Br J Anaesth. 2007 Jul;99(1):18-31
pubmed: 17545555
MMWR Surveill Summ. 2011 Jul 29;60(8):1-19
pubmed: 21796098
J Head Trauma Rehabil. 2014 May-Jun;29(3):E20-9
pubmed: 23756431
Stroke. 1994 Oct;25(10):2091-5
pubmed: 8091457
Neurosci Biobehav Rev. 2021 Jun;125:392-416
pubmed: 33662444
NeuroRehabilitation. 2014;35(4):741-54
pubmed: 25323084
Brain Inj. 2017;31(11):1538-1547
pubmed: 28972396
World Neurosurg. 2019 Nov;131:126-132
pubmed: 31301445
Front Neurol. 2021 Apr 07;12:632572
pubmed: 33897592
Curr Psychiatry Rep. 2003 Oct;5(5):391-9
pubmed: 13678561
Clin Neurophysiol. 2015 Mar;126(3):486-96
pubmed: 24947595
Front Physiol. 2019 Apr 26;10:486
pubmed: 31105589
Brain Res. 2013 Feb 1;1493:80-9
pubmed: 23183041
Dev Med Child Neurol. 1997 Apr;39(4):214-23
pubmed: 9183258
Pharmaceutics. 2019 Nov 12;11(11):
pubmed: 31726721
Brain Res. 2012 Feb 27;1440:47-55
pubmed: 22284619
J Pharmacol Exp Ther. 2005 Dec;315(3):1220-7
pubmed: 16123305
Diabetologia. 2004 Jun;47(6):1047-54
pubmed: 15164170
Brain Res Bull. 2015 Jun;115:17-22
pubmed: 25889001
J Physiol Paris. 1994;88(5):273-7
pubmed: 7787827
Circulation. 2009 Mar 24;119(11):1484-91
pubmed: 19273724
Brain Stimul. 2020 May - Jun;13(3):565-575
pubmed: 32289678
Resuscitation. 2015 Oct;95:1-80
pubmed: 26477410
Dev Neurobiol. 2012 Jun;72(6):766-76
pubmed: 21954122
Circulation. 2015 Oct 20;132(16 Suppl 1):S2-39
pubmed: 26472854